AveXis, Inc.
(NASDAQ : AVXS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading AVXS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$778.89m
INCYIncyte Corporation
0.48%139.641.7%$592.23m
GILDGilead Sciences, Inc.
0.03%67.511.0%$577.68m
CELGCelgene Corporation
0.13%123.381.0%$494.27m
BIIBBiogen Inc.
-0.21%274.821.3%$452.48m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$320.06m
KITEKite Pharma, Inc.
3.14%76.8418.8%$224.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.56m
TSROTESARO, Inc.
4.15%160.0016.1%$189.31m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$173.60m
ILMNIllumina, Inc.
1.72%170.583.7%$172.89m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$150.20m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$142.57m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$135.11m
EXELExelixis, Inc.
2.95%20.917.0%$105.88m

Company Profile

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.